Archive | Selection

RSS feed for this section

How Public Funds Were Spent on Procurement of Medicines in Ukraine’s Hospitals: Interim Analysis for the Ministry of Health, Ukraine

Pharmaceuticals may constitute as much as 40% of the health care budget in low and middle-income countries, yet large portions of the population may lack access to even the most essential medicines. The limited public sector funds are frequently spent on ineffective or unnecessary medications. An analysis of past spending patterns on procurement of medicines will help the Ministry of Health policymakers and key government stakeholders in Ukraine for decisions on adopting the national Essential Medicines List (EML) in practice.

The purpose of this technical brief is twofold:

  • To demonstrate the need to rationalize limited public funds for maximum health impact.
  • To emphasize the need for proper selection of medicines based on WHO recommendations and the rationale for an EML as the sole basis for public sector procurement in Ukraine.

After summarizing high-level data analysis, this technical brief also takes a close look at insulins and analogues that account for the most expenditure.

This [report] is extremely useful. We need to use this information for the purpose of reforming the procurement system as well. The EML has become even more necessary now.”

– Dr. Ihor Perehinets, Deputy Minister of Health of Ukraine

Read full story · Comments are closed

Review of the List of High-Cost Medicines used by the Dominican Republic’s Protected Diseases Program and Planning of Purchases for 2015

The Dominican Republic’s Ministry of Public Health (MPH) is currently implementing an Integrated System for Medicine and Supply Management (known as SUGEMI, for its Spanish acronym) as part of the Ministry’s Public Service Network. Its objective is to improve public access to essential medicines and quality health supplies while promoting the decentralized management and optimum use of available resources. SIAPS is providing support to SUGEMI and collaborated with the Protected Disease Program to procure medicines for 2015. This is a report of the process used to: 1)facilitate for the various PP scientific committees the selection of medicines to be procured in 2015, using medical criteria based on evidence and cost-effectiveness; and 2) estimate and plan for purchases to be made for 2015 of medicines recommended for permanent inclusion on the PP list of medicines.

Read full story · Comments are closed

Haiti Pharmaceutical Sector Technical Assistance Priorities

Download

Access to medicines remains a major issue for the Haitian population. National-level statistics show that less than half the population has acceptable access to medicines. In addition, for those who have access, there is no guarantee of the quality of medicines. As part of the strategy to reform the health system, the MSPP has decided to develop a new NMP. This policy is a commitment from the nation to provide quality pharmaceutical services to the Haitian population on the basis of equity and justice.

Read full story · Comments are closed